NASDAQ, CELG - Celgene Corp
Celgene Corporation and its subsidiaries (collectively ?we? or ?our?) is a
global integrated biopharmaceutical company primarily engaged in the discovery,
development and commercialization of innovative therapies designed to treat
cancer and immune-inflammatory related diseases. Our primary commercial stage
products are REVLIMID? (lenalidomide) and THALOMID? (thalidomide). REVLIMID? was
approved by the U.S. Food and Drug Administration, or FDA, the European
Commission, or EC, Swiss Agency for Therapeutic Products, or Swissmedic and
Australian Therapeutic Goods Administration, for treatment in combination with
dexamethasone for multiple myeloma patients who have received at least one prior
therapy. ...
Read SEC Filing on NASDAQ.com »